Penn's CNDR has expertise in biochemistry, drug discovery, database management and biostatistics, histology, microscopy, molecular biology and tissue culture. In addition, collaborative research opportunities to tap into our extensive collection of bio materials are available through our Biomarkers and Brain Bank programs.
Biosample Request Forms
CNDR experts co-lead two biomarker core programs:
ADNI – the Alzheimer's Disease NeuroImaging Initiative
The study uses imaging techniques and biomarker measures in blood and cerebrospinal fluid specially developed to track changes in the living brain. Researchers hope to identify who is at risk for Alzheimer's, track progression of the disease and devise tests to measure the effectiveness of potential interventions.
PPMI – The Michael J. Fox Foundation's Parkinson's Progression Markers Initiative
a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinsonâ€™s disease progression.
The University of Pennsylvania Alzheimer's Disease Core Center (ADCC), the Penn Udall Center and the Center for Neurodegenerative Disease Research (CNDR) maintain tissue banks, funded by NIH (NIA, NINDS), for human brain samples obtained from patients with:
- Alzheimer's disease (AD)
- Parkinson's Disease (PD) and
- other related neurodegenerative dementias and movement disorders